This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
The futures looked solidly higher Wednesday morning as some of the nervousness over the political and banking situation in Italy appeared to have died down. While concern remains, an imminent crisis seems unlikely now.
DB NBL IAC XOM TGT FN AAPL AVGO TRI ABBV HPQ BRCM ABBV
Fabrinet (FN) reported financial results for Q3 2018 Monday and the results point to a possible boost in optical demand. The company beat on revenue and delivered in-line EPS, but guidance for Q4, which came in above consensus and indicates sequential growth in the quarter, was the catalyst that pushed the stock higher by 7.5% as I write this. I think these results might mean that FN is gearing up for a rebound.
ST. LOUIS, May 08, 2018 (GLOBE NEWSWIRE) -- Stifel Financial Corp. (NYSE:SF) today announced that John Marchetti has joined the firm as Managing Director and Senior Analyst covering the applied technology and communications infrastructure sector. Mr. Marchetti is based in Stifel’s New York office.
MS.PRI FN MS.PRK SF MS.PRE MS.PRF SFN MS.PRG MS MS.PRA SFB SF.PRA
Good day, ladies and gentlemen. Welcome to Fabrinet's Financial Results Conference Call for the Third Quarter of Fiscal Year 2018. At this time all participants are in a listen-only mode. Later we will conduct a question-and-answer session and instruction for how to participate will be given at that time. As a reminder, today's call is being recorded.
49m - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2h - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
22h - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Silicon Investor Message Boards
This table lists all message boards related to FN / Fabrinet on message board site Silicon Investor.
as of ET